To improve the growth inhibition of MCF-7 cells, the time-staggered administration of EGFR inhibitors was conducted followed by DNA intercalating agent doxorubicin, which has been reported to dramatically inhibit a subset of triple-negative breast cancer cells. The gene discussed is EGFR; the disease is triple-negative breast carcinoma.